ReviewCurrent opinion in immunology2009
Adoptive immunotherapy of cancer using CD4(+) T cells.
Review in Current opinion in immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
127 citing papers in PubMed, 1 synthesis or guideline pooled it, 215 citations in OpenAlex.
- Neutrophil-to-Lymphocyte Ratio Predicts PSA Response and Prognosis in Prostate Cancer: A Systematic Review and Meta-Analysis.PloS one · 2016Pooled it
- Peripheral lymphocyte subset variation predicts prostate cancer carbon ion radiotherapy outcomes.Oncotarget · 2016Trial
- Immunotherapy with IL-10- and IFN-γ-producing CD4 effector cells modulate "Natural" and "Inducible" CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer.Cancer immunology, immunotherapy : CII · 2012Trial
- Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Trial
- Deep learning in next-generation vaccine development for infectious diseases.Molecular therapy. Nucleic acids · 2025Review
- The intrinsic expression of NLRP3 in Th17 cells promotes their protumor activity and conversion into Tregs.Cellular & molecular immunology · 2025Article
- Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma.Bone marrow transplantation · 2025Review
- Advances in cancer immunotherapy and future directions in personalized medicine.Open life sciences · 2025Review
- Article
- Article
- The Role of CD4 T Cell Help in CD8 T Cell Differentiation and Function During Chronic Infection and Cancer.Immune network · 2023Review
- Specific recognition of anJournal for immunotherapy of cancer · 2023Article
- Engineered T cell therapy for viral and non-viral epithelial cancers.Cancer cell · 2023Review
- Cytokine profiling of samples positive for Chlamydia trachomatis and Human papillomavirus.PloS one · 2023Article
- The role of CD4 T cells in rejection of solid tumors.Current opinion in immunology · 2022Review
- Stem-like T cells and niches: Implications in human health and disease.Frontiers in immunology · 2022Review
- Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue.Prostate cancer · 2022Article
- Harnessing the IL-21-BATF Pathway in the CD8Cancers · 2021Article
- Organized immune cell interactions within tumors sustain a productive T-cell response.International immunology · 2021Review
- CD4Frontiers in oncology · 2021Article
67 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
CD4(+) T cells are central to the function of the immune system but their role in tumor immunity remains underappreciated. It is becoming clear that there is an enormous diversity of CD4(+) T cell polarization patterns including Th1, Th2, Th17, and regulatory T cells (Tregs). These functionally divergent T cell subsets can have opposing effects -- they can trigger tumor rejection or inhibit treatment after adoptive cell transfer. Some polarized CD4(+) cells have plasticity, and their phenotypes and functions can evolve in vivo. Recent advances in understanding of polarization and differentiation of lymphocytes, as well as some intriguing developments in the clinic, indicate that the use of CD4(+) T cell subsets in the immunotherapy of cancer has unrealized potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.